Nippon Chemiphar Co., Ltd. · TSE:4539
Nippon Chemiphar — Q2 FY2022 Earnings Presentation
21 slides from Nippon Chemiphar's earnings presentation, Nov 14, 2022
Slide 1: Highlights of Second Quarter FY2022 Business Results
（TSE 4539） Highlights of Second Quarter FY2022 Business Results (Year ending March 31, 2023) 1
Slide 2: Contents
Contents I. Summary of Results ………………………… 3 II. Management Strategy…………………………. 9 2
Slide 3: I. Summary of Results
I. Summary of Results 3
Slide 4: Sales, Income
Sales, Income (¥mn) FY2021 FY2022 YOY 2Q % of 2Q % of Change Full Year Progress Amount Sales Amount Sales Amount (%) (Forecast) Rate (%) Net Sales 15,575 100.0 16,237 100.0 662 4.3 35,000 46.4 Pharmaceuticals 15,115 97.0 15,798 97.3 683 4.5 ― ― Generics, proprietary products and new drugs 13,468 86.
Slide 5: Pharmaceutical Sales
Pharmaceutical Sales (¥mn) FY2021 FY2022 2Q % of 2Q % of YOY Full Year Progress Amount Sales Amount Sales (%) (Forecast) Rate (%) Total（① + ②） 13,468 100.0 13,695 100.0 1.7 29,000 47.2 ① Generics 12,581 93.4 13,010 95.0 3.4 27,440 47.4 To medical institutions 12,010 12,423 3.4 26,600 46.7 To other m
Slide 6: Balance Sheet
Balance Sheet (¥mn) March 31, September 2022 30, 2022 Change Components Cash, deposits 1,516 Notes, accounts receivable̶trade (1,080) Current assets 33,495 35,081 1,586 Inventories 1,091 Buildings and structures 43 Non-current assets 15,957 15,576 (381) Investments in securities (567) Total assets 4
Slide 7: Cash Flow
Cash Flow (¥mn) (¥mn) 4,000 2,000 947 897 335 202 1,000 (449) 0 (1,000) 2,000 340 (2,000) 737 470 1,221 1,178 (3,000) 1,161 1,473 926 (4,000) 428 351 0 (214) (590) (576) (148) (5,000) (877) (6,000) (7,000) (2,000) (8,000) 2Q FY2018 2Q FY2019 2Q FY2020 2Q FY2021 2Q FY2022 Operational cash flow Invest
Slide 8: II. Management Strategy
II. Management Strategy 8
Slide 9: Three Plus 1 Principal Goals
Three Plus 1 Principal Goals We striving to increase our capacity to generate earnings through generic drugs and diagnostics and expand our business domains by leveraging alkalizers and new drugs. Further, we intend to strengthen our overseas activities to maximize our corporate value and achieve su
Slide 10: Management Strategy
Management Strategy Many parallel activities leads to achieve our three plus 1 principal goals. We show timeline of new methods from FY2021―2030. Goal Activity 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 DFP-17729: anticancer agent Phase 1/2 for Application, pancreatic cancer Phase 3 approval
Slide 11: Generic Drugs
Generic Drugs With strengthening our quality assurance system and maintaining competitiveness by steadily developing value-added drug formulations, we are promoting efficiency throughout our supply chain. ■Strengthen Generic Drug Business Value-added Products Cutting costs Cutting costs Supports a d
Slide 12: Diagnostics
Diagnostics During the second quarter of FY2022, we established an additional production line for DropScreen measuring kits, and our pharmaceutical MRs will begin promoting these kits during the third quarter. We are currently taking concrete action targeting the utilization of these kits overseas.
Slide 13: Multifaceted Development of Alkalizer
Multifaceted Development of Alkalizer We are conducting multi-faceted development using alkalinization-related technologies and expertise that we cultivated over many years through activities associated with our urine alkalizer, Uralyt. Application of alkalization technologies Anti-cancer agent DFP-
Slide 14: Expand Alkalizers to Cancer (DFP-17729)
Expand Alkalizers to Cancer (DFP-17729) DFP-17729 is the world's first alkalization therapy with cancer as an indication and is currently being developed for therapeutic use in the treatment of pancreatic cancer patients, which are growing in number. It also highly promising as a potential therapy f
Slide 15: Expand Alkalizers to CKD and Health Food
Expand Alkalizers to CKD and Health Food We are striving to develop uses for our alkalinization technologies in treatments that inhibit the progression of chronic kidney disease (CKD) and in functional foods. Inhibit the progression of CKD Trends in the prevalent dialysis patient count • The potenti
Slide 16: Pipeline
Pipeline Function Pre- Item Phase 1 Phase 2 Phase 3 Notes (Target) clinical PPAR-δ agonist ・Finished Phase 1. NC-2400 (Lipid metabolism abnormalities) ・Licensed to Abionyx Pharma SA (France). ・Phase1has ended and we are conducting licensing-out activities. XOR inhibitor NC-2500 ・Explored possibiliti
Slide 17: DFP-14323 (Anti Cancer Agent)
DFP-14323 (Anti Cancer Agent) DFP-14323 targets lung cancer, which causes more deaths than any cancer affecting other parts of the body. We will aim to generate synergy through our sales activities by handling other oncological drugs in addition to DFP-17729. Outline of DFP-14323 Schedule • Chemipha
Slide 18: NC-2800 (Delta Opioid Receptor Agonist)
NC-2800 (Delta Opioid Receptor Agonist) Patients of mood disorders are increasing in number. However, treatment satisfaction remains below 40%. Expected to be first-in-class due to its high levels of safety and efficacy. Outline of NC-2800 Related information • This drug is characterized that less o
Slide 19: Oversea Business
Oversea Business We will realize results generated through business activities aimed at achieving our three goals in Japan overseas as well, particularly in other Asian nations. Activities in Second Quarter FY2022 Vietnam • Achieved smooth progress in terms of efforts aimed at moving product manufac
Slide 20: Plan to Meet Listing Criteria of Prime Market
Plan to Meet Listing Criteria of Prime Market We opted for listing on the TSE’s Prime Market. We plan to achieve full compliance in FY2026 by achieve progress through our management strategy with enhancing IR activities and an increased number of tradable shares.. State of Compliance with Listing Cr
Slide 21: For further information contact
For further information contact: Public Relations Department, Nippon Chemiphar Co., Ltd. E-mail: ir@chemiphar.co.jp Note about Forward-looking Statements and Forecasts Statements made in this Highlights of Business Results, with respect to current plans, estimates, strategies and beliefs, and other